tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris participates in a conference call hosted by Cantor Fitzgerald
The FlyPharvaris participates in a conference call hosted by Cantor Fitzgerald
15d ago
PHVS
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
PremiumRatings
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
2M ago
PHVS
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
PremiumCompany Announcements
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
2M ago
6K
PHVS
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
3M ago
IMNM
KYTX
Pharvaris price target raised to $50 from $44 at Oppenheimer
PremiumThe Fly
Pharvaris price target raised to $50 from $44 at Oppenheimer
3M ago
KALV
PHVS
Pharvaris price target raised to $39 from $32 at Guggenheim
PremiumThe FlyPharvaris price target raised to $39 from $32 at Guggenheim
3M ago
PHVS
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
Premium
Ratings
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
3M ago
PHVS
Pharvaris price target raised to $30 from $27 at BofA
Premium
The Fly
Pharvaris price target raised to $30 from $27 at BofA
3M ago
PHVS
Pharvaris price target raised to $41 from $37 at Morgan Stanley
PremiumThe Fly
Pharvaris price target raised to $41 from $37 at Morgan Stanley
3M ago
PHVS
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
PremiumRatings
Pharvaris’ Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price Target
3M ago
PHVS
Pharvaris price target raised to $38 from $28 at Leerink
PremiumThe Fly
Pharvaris price target raised to $38 from $28 at Leerink
3M ago
PHVS
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
PremiumThe Fly
Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
3M ago
M
W
Promising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
PremiumRatingsPromising Potential of Pharvaris’s Deucrictibant in HAE Treatment Drives Buy Rating
3M ago
PHVS
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
Premium
Ratings
Pharvaris’s IR Deucrictibant Shows Promising Phase 3 Results for HAE Treatment
3M ago
PHVS
Morning Movers: Macy’s dips following third quarter earnings report
Premium
The Fly
Morning Movers: Macy’s dips following third quarter earnings report
3M ago
M
AEO
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
PremiumCompany Announcements
Pharvaris Announces Positive Results from RAPIDe-3 Study for HAE Treatment
3M ago
6K
PHVS
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
PremiumThe Fly
Pharvaris’ deucrictibant meets primary endpoint in HAE attack trial
3M ago
PHVS
Pharvaris Reports Q3 2025 Financial Results and Updates
PremiumCompany Announcements
Pharvaris Reports Q3 2025 Financial Results and Updates
3M ago
PHVS
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
PremiumRatings
Pharvaris: Strong Buy Rating Backed by Promising Clinical Trials and Robust Financial Health
4M ago
PHVS
Pharvaris price target raised to $37 from $34 at Morgan Stanley
PremiumThe FlyPharvaris price target raised to $37 from $34 at Morgan Stanley
4M ago
PHVS
Pharvaris Reports Q3 2025 Financial Results and Business Progress
Premium
Company Announcements
Pharvaris Reports Q3 2025 Financial Results and Business Progress
4M ago
6K
PHVS
Promising Phase 3 Trial Data Drives Buy Rating for Deucrictibant
Premium
Ratings
Promising Phase 3 Trial Data Drives Buy Rating for Deucrictibant
4M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >